| Literatürler Hematoloji Uzmanlık Derneği
Literatür Detay Bilgisi
Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.

Yazarlar : Keating GM, Lyseng-Williamson KA, McKeage K.

Yayın : BioDrugs.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22350448

Konu : Anemi

Literatür İçeriği :  

Abstract

The targeted terminal complement inhibitor eculizumab (Soliris®) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed red cell transfusions. Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated.


Literatür Arşivi

Konusu Aynı Olan Diğer Materyaller
SunumlarVideolarOlgu Tartışması